Asked by: Navendu Mishra (Labour - Stockport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps she has taken to help reduce waiting times for child and adolescent mental health services in Stockport constituency.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
We want to ensure that children and young people get the mental health support they need, including in the Stockport constituency, and overall spending on mental health has increased by more than £4.7 billion in cash terms since 2018/19. This has enabled an expansion of child and young people's mental health services. As of January 2024, the latest data from NHS Digital shows there were 758,485 children and young people aged under 18 years old, supported through National Health Service funded mental health services with at least one contact.
We have introduced two waiting-time standards for children and young people. The first is for 95% of children, up to 19 years old, with eating disorders to receive treatment within one week for urgent cases, and four weeks for routine cases. The second is for 50% of patients of all ages experiencing a first episode of psychosis to receive treatment within two weeks of referral.
NHS England is developing a new waiting time measure for children and their families and carers to start to receive community-based mental health care within four weeks from referral. NHS England began publishing this new data in 2023 to improve transparency and drive local accountability.
Asked by: Caroline Lucas (Green Party - Brighton, Pavilion)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.
The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.
The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.
Asked by: Ellie Reeves (Labour - Lewisham West and Penge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will commission research into the impact of (a) autism and (b) ADHD on women.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is currently funding research to address measurement bias in the assessment of the presentation of autism in women, and to develop a new psychometric tool assessing the female-dominant phenotype of autism. The NIHR previously funded a study to improve the accuracy and efficiency of autism assessment for adults which, while not specific to women, will be relevant to their experiences of receiving a diagnosis. The NIHR has also funded research into topics that impact autistic individuals differently, for example how to adapt suicide safety plans to address self-harm, suicidal ideation, and suicide behaviours in autistic adults.
The NIHR welcomes funding applications for research into any aspect of human health, including the impact of autism and attention deficit hyperactivity disorder on women. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. In all disease areas, the amount of NIHR funding depends on the volume and quality of scientific activity.
Asked by: Kerry McCarthy (Labour - Bristol East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many patients in the South West have been eligible for pre-implantation genetic testing for monogenic disorders in each of the last five years.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Pre-implantation Genetic Testing (PGT) is used to identify genetic anomalies in embryos created through in-vitro fertilisation. Over 600 genetic conditions can currently be tested for using this technique, as licensed by the Human Fertilisation and Embryology Authority. NHS England has commissioned five centres to provide PGT to patients in England. The number of PGT cycles undertaken has increased from 223 patients in 2009 to 620 in 2019, but NHS England does not have access to data that describes the geographical profile of the people that have used the National Health Service or privately commissioned PGT services.
Asked by: Neale Hanvey (Alba Party - Kirkcaldy and Cowdenbeath)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many of the reports in relation to (a) fatal outcomes and (b) adverse reactions in patients who have received a COVID-19 vaccine received by the Medicines and Healthcare products Regulatory Agency under its statutory function to operate a system of post marketing surveillance were judged as (i) likely, (ii) possibly and (iii) unlikely to have been caused by Covid-19 vaccine; and how many such reports lacked sufficient information to make a judgement.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
While the Medicines and Healthcare products Regulatory Agency carefully assesses Yellow Card reports of suspected adverse reactions, including those with a fatal outcome, to determine whether additional information is required to facilitate assessment of the link between a medicine and the reported adverse event, they do not assign causality at the level of individual reports.
Cumulatively, Yellow Card data is thoroughly analysed for patterns or evidence which might suggest a causal link between the vaccination and the reported reaction, alongside other relevant data. In relation to fatal reports, it is the role of a Coroner to determine the likely cause of death for an individual.
Asked by: Wes Streeting (Labour - Ilford North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much NHS England spent on agency staff in each year since 2010.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The first full financial year for which NHS England was in existence, as the NHS Commissioning Board, was 2013/14. NHS England only holds information on agency spend in combination with other commissioning bodies, for instance integrated care boards, formerly known as clinical commissioning groups. The following table shows the total spent on agency staff in NHS England and the commissioning bodies, each year since 2013/14 to 2022/23:
Year | Spend |
2013/14 | £240,000,000 |
2014/15 | £300,000,000 |
2015/16 | £310,000,000 |
2016/17 | £270,000,000 |
2017/18 | £190,000,000 |
2018/19 | £160,000,000 |
2019/20 | £130,000,000 |
2020/21 | £160,000,000 |
2021/22 | £160,000,000 |
2022/23 | £210,000,000 |
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many equines with passports issued by Weatherbys passport issuing agencies were registered as being in training when they were slaughtered in (a) 2021, (b) 2022 and (c) 2023.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
548 horses were slaughtered in 2022, and 721 horses were slaughtered in 2023. Tables showing the number of horses slaughtered in abattoirs in 2022 and 2023 by passport issuing agency and age are attached, due to the size of the data. The information requested on the number of equines registered as being in training when slaughtered is not held.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will publish a breakdown by passport issuing agency and age of horses slaughtered in abattoirs in (a) 2022 and (b) 2023.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
548 horses were slaughtered in 2022, and 721 horses were slaughtered in 2023. Tables showing the number of horses slaughtered in abattoirs in 2022 and 2023 by passport issuing agency and age are attached, due to the size of the data. The information requested on the number of equines registered as being in training when slaughtered is not held.
Asked by: Geoffrey Cox (Conservative - Torridge and West Devon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) promote better awareness within the NHS of the symptoms of Lyme disease and (b) speed up (i) testing and (ii) analysis of test results for Lyme disease.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The National Institute for Health and Care Excellence’s (NICE) Clinical Knowledge Summaries (CKS) are specifically aimed at general practices (GPs), and cover the availability of testing services. The entomology group in the UK Health Security Agency (UKHSA) also has a tick awareness scheme, which sends out information on avoiding tick bites in a spring campaign, and supports local authorities in areas with a high prevalence of Lyme disease. Further information on Lyme disease, access to testing, and the NICE’s CKS’ is available respectively at the links below:
https://www.gov.uk/government/collections/lyme-disease-guidance-data-and-analysis
https://www.nice.org.uk/guidance/ng95
https://cks.nice.org.uk/topics/lyme-disease/management/management/
All confirmatory testing in England is performed by the Rare and Imported Pathogens Laboratory (RIPL). Delays may occur in the referring laboratory when submitting the sample, during testing at the RIPL, or when accessing the results, which are sent back electronically, before being passed onto GPs. Only the RIPL is within the UKHSA’s control, and the RIPL is planning to introduce new technology to speed up tests for neuroborreliosis.
National data analysis is released through the Fingertips system, which is regularly updated. The annual number of cases of Lyme disease varies from year to year, depending on weather conditions in the Lyme season, the effects of weather and human activities on animals that harbor the disease, and the tick population. Further information on the Fingertips system is available at the following link:
https://fingertips.phe.org.uk/profile/health-protection/data
Asked by: Matt Western (Labour - Warwick and Leamington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure people with diabetes can continue to access the insulin they need.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
We are aware of supply issues with some insulin products, however the vast majority are in stock. Comprehensive management guidance on alternative products has been issued to the National Health Service where needed.
The medicine supply chain is highly regulated, complex, and global. Supply disruption is an issue which affects the United Kingdom, as well as the other countries around the world, and it can have a variety of causes, including manufacturing issues, problems with access to raw ingredients, and sudden spikes in demand.
There is a team within the Department that deals specifically with medicine supply problems. It has well-established tools and processes to manage medicine supply issues, working closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England, and others operating in the supply chain, to help prevent shortages and expedite resupply as soon as possible, to ensure that the risks to patients are minimised.